BR0100156A - Compostos tetrazol como ligandos de receptor de tiróide - Google Patents

Compostos tetrazol como ligandos de receptor de tiróide

Info

Publication number
BR0100156A
BR0100156A BR0100156-6A BR0100156A BR0100156A BR 0100156 A BR0100156 A BR 0100156A BR 0100156 A BR0100156 A BR 0100156A BR 0100156 A BR0100156 A BR 0100156A
Authority
BR
Brazil
Prior art keywords
tetrazole compounds
thyroid
receptor ligands
thyroid receptor
pharmaceutically acceptable
Prior art date
Application number
BR0100156-6A
Other languages
English (en)
Inventor
Yuan-Ching Phoebe Chiang
Gary Erik Aspnes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0100156A publication Critical patent/BR0100156A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS TETRAZOL COMO LIGANDOS DE RECEPTOR DE TIRóIDE". A presente invenção descreve compostos de tetrazol de Fórmula I, seus estereoisómeros, sais farmaceuticamente aceitáveis ou pródrogas, ou sais farmaceuticamente aceitáveis das suas pró-drogas. A invenção também descreve as composições compreendendo os compostos de tetrazol e os métodos para o tratamento da obesidade, diabetes, aterosclerose, hipertensão, doença coronária do coração, hipercolesterolemia, hiperlipidemia, doença da tiróide, câncer da tiróide, hipotiroidismo, depressão, glaucoma, arritmias cardíacas, insuficência cardíaca congestiva, e osteoporose utilizando compostos de tetrazol.
BR0100156-6A 2000-01-25 2001-01-25 Compostos tetrazol como ligandos de receptor de tiróide BR0100156A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17798700P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
BR0100156A true BR0100156A (pt) 2003-04-08

Family

ID=22650723

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0100156-6A BR0100156A (pt) 2000-01-25 2001-01-25 Compostos tetrazol como ligandos de receptor de tiróide

Country Status (5)

Country Link
US (2) US6441015B2 (pt)
EP (1) EP1127882A1 (pt)
JP (1) JP3832563B2 (pt)
BR (1) BR0100156A (pt)
CA (1) CA2332066C (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2002076390A2 (en) * 2001-03-23 2002-10-03 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
WO2004065372A1 (en) * 2003-01-20 2004-08-05 Medigene Aktiengesellschaft Tetrazole-functionalized amino acids, their production and use
JP2006519229A (ja) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
JP4602218B2 (ja) * 2005-10-18 2010-12-22 矢崎総業株式会社 レバー式コネクタ
ATE478053T1 (de) * 2007-06-06 2010-09-15 Torrent Pharmaceuticals Ltd Neuartige verbindungen
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR101643721B1 (ko) * 2010-11-09 2016-07-28 후지안 하이시 파머수티클스, 인코포레이티드 키나아제 활성을 증진시키기 위한 화합물 및 이의 응용
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP4167986A4 (en) * 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
ZA865090B (en) 1985-07-22 1988-02-24 Riker Laboratories Inc Substituted di-t-butylphenols
CA1320490C (en) 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4992576A (en) 1987-01-12 1991-02-12 Eli Lilly And Company Intermediates for leukotriene antagonists
JP2627003B2 (ja) * 1989-01-25 1997-07-02 塩野義製薬株式会社 ジーｔｅｒｔ―ブチルヒドロキシフェニルチオ誘導体
JPH05313274A (ja) * 1992-05-13 1993-11-26 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
US6100259A (en) * 1997-01-21 2000-08-08 Smithkline Beecham Corporation Cannabinoid receptor modulators
WO1998042650A2 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II

Also Published As

Publication number Publication date
CA2332066C (en) 2006-07-04
US6441015B2 (en) 2002-08-27
JP2001226359A (ja) 2001-08-21
US20020006946A1 (en) 2002-01-17
CA2332066A1 (en) 2001-07-25
US20030040535A1 (en) 2003-02-27
JP3832563B2 (ja) 2006-10-11
EP1127882A1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
CA2332066A1 (en) Tetrazole compounds as thyroid receptor ligands
PT1088819E (pt) Derivados de 6-azauracilo como lignados de receptores da tiroide
DK1033364T3 (da) Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
BR0101527A (pt) Ligandos de receptores de tiróide
AP2001002259A0 (en) Oxamic acids and derivatives as thyroid receptor ligands.
CY1105603T1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
CR6742A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo
BR0212477A (pt) 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
CY1108969T1 (el) Ενωσεις 1,2-διϋδροπυριδινης, διεργασια για την παρασκευη των ιδιων και χρηση εξ αυτων
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
WO2006128056A3 (en) Novel phosphinic acid-containing thyromimetics
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
WO2006128055A3 (en) Novel phosphorus-containing thyromimetics
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
DE60027144D1 (de) Hydroxamsäure-derivate
AU1432402A (en) Medicinal compositions
BR0316962A (pt) Aminoalcoxiindóis como ligantes para o receptor de 5-ht6 para o tratamento de distúrbios do snc
BG104447A (en) Biphenylamidine derivatives
DK1059283T3 (da) Fremgangsmåde til fremstilling af neuraminidase-inhibitor ro-64-0796
WO2001016096A3 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
WO2005065315A3 (en) Bone targeting compounds for delivering agents to the bone for interaction therewith
EP1253139A3 (en) Multioligoanilinated fullerenes
BR0009549A (pt) Uso das arilalcanoil piridazinas
DE60325172D1 (de) Verbindungen als semaphorininhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9, 10AE 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.